Table 1.
General information of 8 refractory AOSD patients receiving TCZ therapy.
| No. case | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
|---|---|---|---|---|---|---|---|---|---|
| Gender | female | female | female | female | female | female | female | female | |
| Age (years old) | 21 | 47 | 63 | 62 | 32 | 34 | 24 | 46 | |
| Multi-system involvement | Y | Y | Y | Y | Y | Y | Y | ||
| Disease duration (month) | 12 | 6 | 3 | 14 | 84 | 20 | 24 | 26 | |
| Yamaguchi’s criteria (>5 criteria, at least 2 major criteria) | |||||||||
| Major Criterias | Fever ≥39.0 °C, over 1 week | Y | Y | Y | Y | Y | Y | Y | Y |
| Arthritis over 2 weeks | Y | Y | Y | Y | Y | Y | Y | Y | |
| Typical rashes | Y | Y | Y | Y | Y | Y | Y | ||
| White blood cells ≥10*10^9/L | Y | Y | Y | Y | Y | Y | |||
| Minor Criterias | Sore throat | Y | Y | Y | Y | ||||
| lymph nodes and (or) spleen enlargement | Y | Y | Y | Y | Y | Y | |||
| Hepatic dysfunction | Y | Y | Y | Y | |||||
| Negative RF and ANA | Y | Y | Y | Y | Y | Y | Y | ||
| Laboratory Examination | White blood cells (10^9/L) | 12.9 | 13 | 17.7 | 9.78 | 16.4 | 14.9 | 11.3 | 7.78 |
| Ferritin (ng/mL) | 1060.9 | 28.5 | 789.8 | 5135 | 18.6 | 334.8 | 412.3 | 1500 | |
| ESR (mm/h) | 75 | 6 | 55 | 93 | 34 | 41 | 76 | 50 | |
| CRP (mg/l) | 54 | 2.5 | 99.9 | 89.5 | 20.8 | 95 | 32.4 | 28 | |
| Previous Treatments | Pred maximum-current dosage (mg/d) | 60–15 | 500–30 | 120–100 | 80–20 | 40–30 | 240–80 | 160–80 | 120–40 |
| Immunosuppressive drugs | MTX, HCQ, MMF, LEF | CsA, MTX, IVIG, Thalidu-mide | / | HCQ, T2, MTX | MTX CsA, LEF, IFX | MTX | MTX CsA | CTX | |
| Dosage of TCZ | mg/kg,q4w | 8 mg/kg, *13 | 4 mg/kg, *6 | 4 mg/kg *6 | 4 mg/kg, *4 | 8 mg/kg, *6 | 8 mg/kg, *2 | 8 mg/kg, *8 | 8 mg/kg, *7 |
MTX: methotrexate; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; LEF: leflunomide; CsA: cyclosporine A; IVIG: intravenous immunoglobulin; T2: tripterygium glycosides.